Also, a reverse merger by Synta Pharmaceuticals and Madrigal Pharmaceuticals will create a company that focuses on non-alcoholic steatohepatitis and Kaiser Permanente has launched a biobank to develop new diagnoses and treatment plans.
Also, Intel healthcare guru Eric Dishman has been selected to lead up the Precision Medicine Initiative.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
Also, J. Craig Venter's crew has lab-engineered a species of bacteria out of the minimum level of genetic code.
Learn about the Trans-Pacific Partnership and the latest FDA approvals.
Also news on Cell Therapy, Spark Therapeutics and the quest for an electronic data standard.
The newly approved therapy comes with a hefty price tag.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
"Cyborg brains," in the form of brain implants, are in development at the University of Southern California.
Also, Teva talks drug prices; security wonks talk medical device hacks, and ugly talk at the Anthem-Aetna hearings.
Also, MacArthur Awards are in, Medtronic makes its eighth deal of the year, millennials share their opinions on wearables, and does Genentech really have a $5 billion MS drug in the pipeline?
Also some great insight on how patients see genomics, good news for Roche & PhRMA's new lobbyist has arrived?
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
An interview with Martin Shkreli four years ago when he was heading up his first biotech company, Retrophin
Novartis has now launched "Novartis Access" - which will be a portfolio of affordable medicines used to treat diseases in low-income countries.
Turing Pharmaceuticals and Martin Shkreli blink (maybe), Anthem-Aetna Capitol Hill testimony begins, and Nestle gets deeper into the medical research.
Big news well beyond Turing: Human Longevity has dropped exome sequencing prices; AstraZeneca will try crowdsourcing cancer; the Federal Health IT Strategic Plan is out; and Adventist Health System is paying more than $100 million in a whistleblower case.
Also, the narrative shifts for FDA nominee Robert Califf, good news on Merck's c. diff treatment, and here's one part of Obamacare everyone hates.